1. Home
  2. UBS vs GILD Comparison

UBS vs GILD Comparison

Compare UBS & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo UBS Group AG Registered

UBS

UBS Group AG Registered

HOLD

Current Price

$48.97

Market Cap

154.1B

Sector

Finance

ML Signal

HOLD

Logo Gilead Sciences Inc.

GILD

Gilead Sciences Inc.

HOLD

Current Price

$125.59

Market Cap

168.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UBS
GILD
Founded
1862
1987
Country
Switzerland
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
154.1B
168.6B
IPO Year
2014
2003

Fundamental Metrics

Financial Performance
Metric
UBS
GILD
Price
$48.97
$125.59
Analyst Decision
Buy
Strong Buy
Analyst Count
2
18
Target Price
$60.30
$148.39
AVG Volume (30 Days)
2.2M
6.4M
Earning Date
04-29-2026
05-07-2026
Dividend Yield
1.29%
2.55%
EPS Growth
N/A
1684.21
EPS
N/A
1.61
Revenue
N/A
$24,689,000,000.00
Revenue This Year
$7.40
$4.68
Revenue Next Year
$2.83
$6.04
P/E Ratio
$17.22
$78.17
Revenue Growth
N/A
9.98
52 Week Low
$30.39
$107.19
52 Week High
$49.36
$157.29

Technical Indicators

Market Signals
Indicator
UBS
GILD
Relative Strength Index (RSI) 63.20 40.15
Support Level $46.47 $116.55
Resistance Level $49.36 $126.46
Average True Range (ATR) 0.80 3.58
MACD -0.08 -0.57
Stochastic Oscillator 97.82 25.87

Price Performance

Historical Comparison
UBS
GILD

About UBS UBS Group AG Registered

UBS is a global financial institution built around its core strength in wealth management, serving high and ultra-high-net-worth individuals. In Switzerland, it also operates as a traditional retail and commercial bank. Its investment bank and asset management divisions complement the wealth business, providing tailored solutions to UBS clients while serving third-party customers by leveraging UBS' global reach and expertise.

About GILD Gilead Sciences Inc.

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Share on Social Networks: